{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.70","spread":"4.70","upperLimit":"19.88","value":"10.61"},{"groupId":"OG001","lowerLimit":"7.49","spread":"7.49","upperLimit":"16.16","value":"10.74"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"PFS was defined as the duration from the date of randomization to either progressive disease (PD) or death, whichever comes first. IMWG criteria for PD: \\>=25% from lowest response level in serum M-component (the absolute increase must be \\>=0.5 gram per deciliter \\[g/dL\\]) and/or in urine M-component (the absolute increase must be \\>=200 mg/24 hour); only in participants without measurable serum and urine M-protein levels: increase of \\>=25% in the difference between involved and uninvolved free light chain levels and the absolute increase must be \\>10 mg/dL. BMPC%: the absolute % must be \\>=10%; definite increase in size of existing bone lesions or soft tissue plasmacytomas; definite development of new bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \\>11.5 milligrams per deciliter (mg/dL) or 2.65 millimoles per liter \\[mmol/L\\]) that can be attributed solely to PC proliferative disorder.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received carfilzomib 20 milligram per meter square (mg/m\\^2) intravenously (IV) on Cycle 1 Day 1 and then 70 mg/m\\^2 on Cycle 1 Days 8 and 15, and thereafter on Days 1, 8, 15 from Cycle 2 onwards. Participants received dexamethasone 20 milligrams (mg) on Cycle 1 Days 1 and 2, and 40 mg IV or orally on Days 8, 15, 22 of Cycle 1. Participants then received dexamethasone 40 mg IV or orally on Days 1, 8, 15 and 22 of Cycles 2-9, then on Days 1, 8, 15 from Cycle 10 onwards, until confirmed progressive disease (PD), death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study, whichever occurs first. Each cycle of 28 days.","id":"OG000","title":"Arm A: Carfilzomib+Dexamethasone (Kd)"},{"description":"Participants received daratumumab 1800 mg by SC injection (Dara-SC) on Days 1, 8, 15, 22 of Cycle 1 and 2, Days 1 and 15 of Cycle 3-6, and on Day 1 from Cycle 7 onwards. Participants received carfilzomib 20 mg/m\\^2 IV on Cycle 1 Day 1 and then 70 mg/m\\^2 on Cycle 1 Days 8 and 15, and Days 1, 8 and 15 from Cycle 2 onwards. Participants received dexamethasone 20 mg on Cycle 1 Days 1 and 2 and 40 mg IV or orally on Days 8, 15, 22 of Cycle 1. Participants then received dexamethasone 40 mg IV or orally on Days 1, 8, 15 and 22 of Cycles 2-9, then on Days 1, 8, 15 from Cycle 10 onwards, until confirmed PD, death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study, whichever occurs first. Each cycle of 28 days.","id":"OG001","title":"Arm B: Dara-SC in Combination With Kd (DKd)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) analysis set included all participants who were randomized in the study. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 3 years and 7 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}